Literature DB >> 33473210

Restoring metabolism of myeloid cells reverses cognitive decline in ageing.

Amira Latif-Hernandez1, Melanie R McReynolds2,3, Paras S Minhas1,4,5, Aarooran S Durairaj1, Qian Wang1, Amanda Rubin1,4, Amit U Joshi6, Joy Q He7, Esha Gauba1, Ling Liu2,3, Congcong Wang1, Miles Linde8, Yuki Sugiura9, Peter K Moon1, Ravi Majeti8, Makoto Suematsu9, Daria Mochly-Rosen6, Irving L Weissman7, Frank M Longo1, Joshua D Rabinowitz2,3, Katrin I Andreasson10,11,12.   

Abstract

Ageing is characterized by the development of persistent pro-inflammatory responses that contribute to atherosclerosis, metabolic syndrome, cancer and frailty1-3. The ageing brain is also vulnerable to inflammation, as demonstrated by the high prevalence of age-associated cognitive decline and Alzheimer's disease4-6. Systemically, circulating pro-inflammatory factors can promote cognitive decline7,8, and in the brain, microglia lose the ability to clear misfolded proteins that are associated with neurodegeneration9,10. However, the underlying mechanisms that initiate and sustain maladaptive inflammation with ageing are not well defined. Here we show that in ageing mice myeloid cell bioenergetics are suppressed in response to increased signalling by the lipid messenger prostaglandin E2 (PGE2), a major modulator of inflammation11. In ageing macrophages and microglia, PGE2 signalling through its EP2 receptor promotes the sequestration of glucose into glycogen, reducing glucose flux and mitochondrial respiration. This energy-deficient state, which drives maladaptive pro-inflammatory responses, is further augmented by a dependence of aged myeloid cells on glucose as a principal fuel source. In aged mice, inhibition of myeloid EP2 signalling rejuvenates cellular bioenergetics, systemic and brain inflammatory states, hippocampal synaptic plasticity and spatial memory. Moreover, blockade of peripheral myeloid EP2 signalling is sufficient to restore cognition in aged mice. Our study suggests that cognitive ageing is not a static or irrevocable condition but can be reversed by reprogramming myeloid glucose metabolism to restore youthful immune functions.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33473210      PMCID: PMC8274816          DOI: 10.1038/s41586-020-03160-0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  46 in total

Review 1.  Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans.

Authors:  Claudio Franceschi; Miriam Capri; Daniela Monti; Sergio Giunta; Fabiola Olivieri; Federica Sevini; Maria Panagiota Panourgia; Laura Invidia; Laura Celani; Maria Scurti; Elisa Cevenini; Gastone C Castellani; Stefano Salvioli
Journal:  Mech Ageing Dev       Date:  2006-11-20       Impact factor: 5.432

Review 2.  The elephant in the room - healthy brains in later life, epidemiology and public health.

Authors:  Carol Brayne
Journal:  Nat Rev Neurosci       Date:  2007-02-14       Impact factor: 34.870

Review 3.  Human cognitive aging: corriger la fortune?

Authors:  Ulman Lindenberger
Journal:  Science       Date:  2014-10-31       Impact factor: 47.728

Review 4.  Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.

Authors:  Luigi Ferrucci; Elisa Fabbri
Journal:  Nat Rev Cardiol       Date:  2018-09       Impact factor: 32.419

Review 5.  The twilight of immunity: emerging concepts in aging of the immune system.

Authors:  Janko Nikolich-Žugich
Journal:  Nat Immunol       Date:  2017-12-14       Impact factor: 25.606

6.  Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice.

Authors:  Saul A Villeda; Kristopher E Plambeck; Jinte Middeldorp; Joseph M Castellano; Kira I Mosher; Jian Luo; Lucas K Smith; Gregor Bieri; Karin Lin; Daniela Berdnik; Rafael Wabl; Joe Udeochu; Elizabeth G Wheatley; Bende Zou; Danielle A Simmons; Xinmin S Xie; Frank M Longo; Tony Wyss-Coray
Journal:  Nat Med       Date:  2014-05-04       Impact factor: 53.440

Review 7.  Microglia in Alzheimer's disease.

Authors:  Heela Sarlus; Michael T Heneka
Journal:  J Clin Invest       Date:  2017-09-01       Impact factor: 14.808

Review 8.  Microglial malfunction: the third rail in the development of Alzheimer's disease.

Authors:  Siddhita D Mhatre; Connie A Tsai; Amanda J Rubin; Michelle L James; Katrin I Andreasson
Journal:  Trends Neurosci       Date:  2015-10       Impact factor: 13.837

9.  The ageing systemic milieu negatively regulates neurogenesis and cognitive function.

Authors:  Saul A Villeda; Jian Luo; Kira I Mosher; Bende Zou; Markus Britschgi; Gregor Bieri; Trisha M Stan; Nina Fainberg; Zhaoqing Ding; Alexander Eggel; Kurt M Lucin; Eva Czirr; Jeong-Soo Park; Sebastien Couillard-Després; Ludwig Aigner; Ge Li; Elaine R Peskind; Jeffrey A Kaye; Joseph F Quinn; Douglas R Galasko; Xinmin S Xie; Thomas A Rando; Tony Wyss-Coray
Journal:  Nature       Date:  2011-08-31       Impact factor: 49.962

10.  Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research.

Authors:  Colm Cunningham; Edel Hennessy
Journal:  Alzheimers Res Ther       Date:  2015-03-24       Impact factor: 6.982

View more
  59 in total

1.  Single-cell transcriptomics identifies premature aging features of TERC-deficient mouse brain and bone marrow.

Authors:  Chunying Yang; Yidan Pang; Yigang Huang; Fang Ye; Xiaoyi Chen; Youshui Gao; Changqing Zhang; Lufeng Yao; Junjie Gao
Journal:  Geroscience       Date:  2022-05-11       Impact factor: 7.713

2.  Aging Leukocytes and the Inflammatory Microenvironment of the Adipose Tissue.

Authors:  Korbyn J V Dahlquist; Christina D Camell
Journal:  Diabetes       Date:  2022-01-01       Impact factor: 9.461

3.  Macrophage monocarboxylate transporter 1 promotes peripheral nerve regeneration after injury in mice.

Authors:  Mithilesh Kumar Jha; Joseph V Passero; Atul Rawat; Xanthe Heifetz Ament; Fang Yang; Svetlana Vidensky; Samuel L Collins; Maureen R Horton; Ahmet Hoke; Guy A Rutter; Alban Latremoliere; Jeffrey D Rothstein; Brett M Morrison
Journal:  J Clin Invest       Date:  2021-11-01       Impact factor: 14.808

Review 4.  The adaptive aging brain.

Authors:  Liviu Aron; Joseph Zullo; Bruce A Yankner
Journal:  Curr Opin Neurobiol       Date:  2021-10-22       Impact factor: 6.627

5.  IL-37 expression reduces acute and chronic neuroinflammation and rescues cognitive impairment in an Alzheimer's disease mouse model.

Authors:  Niklas Lonnemann; Shirin Hosseini; Melanie Ohm; Robert Geffers; Karsten Hiller; Charles A Dinarello; Martin Korte
Journal:  Elife       Date:  2022-08-30       Impact factor: 8.713

Review 6.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

Review 7.  Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer's Disease.

Authors:  Tamas Fulop; Shreyansh Tripathi; Serafim Rodrigues; Mathieu Desroches; Ton Bunt; Arnold Eiser; Francois Bernier; Pascale B Beauregard; Annelise E Barron; Abdelouahed Khalil; Adam Plotka; Katsuiku Hirokawa; Anis Larbi; Christian Bocti; Benoit Laurent; Eric H Frost; Jacek M Witkowski
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-04       Impact factor: 2.570

Review 8.  Senescent Microglia: The Key to the Ageing Brain?

Authors:  Eleanor K Greenwood; David R Brown
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

9.  Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer's Disease and Parkinson's Disease.

Authors:  Danielle Klinger; Brian L Hill; Noam Barda; Eran Halperin; Ofer N Gofrit; Charles L Greenblatt; Nadav Rappoport; Michal Linial; Hervé Bercovier
Journal:  Vaccines (Basel)       Date:  2021-05-11

Review 10.  EP2 Antagonists (2011-2021): A Decade's Journey from Discovery to Therapeutics.

Authors:  Madison N Sluter; Ruida Hou; Lexiao Li; Nelufar Yasmen; Ying Yu; Jiawang Liu; Jianxiong Jiang
Journal:  J Med Chem       Date:  2021-08-05       Impact factor: 8.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.